Jacobson Pharma Corporation Limited

SEHK:2633 Stock Report

Market Cap: HK$1.2b

Jacobson Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Derek Sum

Chief executive officer

HK$13.7m

Total compensation

CEO salary percentage25.4%
CEO tenure8.4yrs
CEO ownership60.2%
Management average tenureno data
Board average tenure8.3yrs

Recent management updates

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Recent updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jul 14
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Feb 09
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Nov 29
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11
Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27
Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03
Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

CEO Compensation Analysis

How has Derek Sum's remuneration changed compared to Jacobson Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

HK$186m

Dec 31 2023n/an/a

HK$221m

Sep 30 2023n/an/a

HK$217m

Jun 30 2023n/an/a

HK$234m

Mar 31 2023HK$14mHK$3m

HK$251m

Dec 31 2022n/an/a

HK$207m

Sep 30 2022n/an/a

HK$203m

Jun 30 2022n/an/a

HK$190m

Mar 31 2022HK$5mHK$3m

HK$178m

Dec 31 2021n/an/a

HK$166m

Sep 30 2021n/an/a

HK$154m

Jun 30 2021n/an/a

HK$164m

Mar 31 2021HK$5mHK$4m

HK$174m

Dec 31 2020n/an/a

HK$183m

Sep 30 2020n/an/a

HK$191m

Jun 30 2020n/an/a

HK$203m

Mar 31 2020HK$5mHK$4m

HK$214m

Sep 30 2019n/an/a

HK$273m

Jun 30 2019n/an/a

HK$259m

Mar 31 2019HK$5mHK$4m

HK$245m

Dec 31 2018n/an/a

HK$235m

Sep 30 2018n/an/a

HK$219m

Jun 30 2018n/an/a

HK$211m

Mar 31 2018HK$6mHK$4m

HK$202m

Compensation vs Market: Derek's total compensation ($USD1.75M) is above average for companies of similar size in the Hong Kong market ($USD358.54K).

Compensation vs Earnings: Derek's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Derek Sum (61 yo)

8.4yrs

Tenure

HK$13,692,000

Compensation

Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...


Board Members

NamePositionTenureCompensationOwnership
Kwong Yip Sum
Chairman8.4yrsHK$13.69m60.18%
HK$ 750.7m
Yue Wai Pun
VP of Administration & Executive Director7.4yrsHK$4.53m0.42%
HK$ 5.2m
Chun Leung Yim
Executive Director8.3yrsHK$8.03m2.04%
HK$ 25.5m
Sing Kwong Lam
Independent Non-Executive Director8.3yrsHK$226.00kno data
Chun Man Young
Independent Non-Executive Director7.9yrsHK$226.00kno data
Kwok Chow
Member of Scientific Advisory Committee8.3yrsno datano data
Wai Lee
Member of Scientific Advisory Committee8.3yrsno datano data
Hoi Yee Tong
Member of Scientific Advisory Committee8.3yrsno datano data
Chi Kei Wong
Non-Executive Director & Member of Scientific Advisory Committee8.3yrsHK$226.00kno data
Kwing Tong Lam
Independent Non-Executive Director7.9yrsHK$226.00k0.030%
HK$ 378.0k

8.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 2633's board of directors are considered experienced (8.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.